运动诱导的信号在缓解神经元胰岛素耐药性的过程中
Ishitha Reddy1, Chinmoy Sankar Dey1
1Kusuma School of Biological Sciences, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, India.
The Journal of physiology
|April 2, 2025
概括
定期炼可以改善大脑健康,并对抗2型糖尿病等代谢障碍. 运动诱导的信号分子增强神经保护和胰岛素敏感性,为阿尔茨海默病等疾病提供非药物治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 代谢健康 代谢健康
- 运动生理学 运动生理学
背景情况:
- 运动对葡萄糖平衡,胰岛素敏感性,神经保护和神经发生有积极的影响.
- 患有2型糖尿病的人患阿尔茨海默病的风险增加.
- 运动为管理代谢障碍提供了一个非药物战略.
研究的目的:
- 探索运动激活的分子信号通路.
- 了解运动诱导的信号如何改善神经元的胰岛素抵抗.
- 研究运动作为阿尔茨海默病治疗干预措施的潜力.
主要方法:
- 对参与运动对大脑影响的分子信号通路的审查.
- 分析各种分子级联之间的交叉对话.
- 识别关键分子和途径,调解运动效益.
主要成果:
- 运动唤起循环分子,这些分子将运动的好处传递到整个身体和大脑.
- 运动信号通路,包括SIRT1/PGC-1α和BDNF/TrkB,在改善与阿尔茨海默病相关的条件方面显示出希望.
- 运动可以作为一个绕道机制来改善神经元的胰岛素抵抗.
结论:
- 运动诱导的分子信号是未来研究的关键领域.
- 了解这些途径对于开发神经退行性和代谢性疾病的治疗策略至关重要.
- 对运动分子机制的进一步研究可能会导致对阿尔茨海默氏症和2型糖尿病的新治疗方法.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.0K
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143


